Seroprevalence of COVID-19 Antibodies among Patients with Haemophilia

Abstract

comorbidities affecting the patient determine the severity. Method: The place of study was Lok Nayak Hospital located in New Delhi. The type of study was prospective observational. The incorporation of 112 subjects was done for the study on the basis of inclusion criteria. Informed consent was obtained from the patients after which they underwent rigorous history taking, general and systemic examination and relevant investigations. Interpretation and compilation were done with MS Excel (R) Office 365, GraphPad Prism 8.4.2 and Statistical Package for Social Sciences version 25. Seroprevalence was estimated by measuring the COVID-19 antibodies in these patients’ serum with an ELISA kit. Results: Seroprevalence in the current study came out to be 13.39%, which was significantly lower as compared to the overall pooled seroprevalence of India. This was due to better knowledge, awareness and care taken by these patients towards the disease during the pandemic times. COVID-19 antibody index was in low ranges in patients with haemophilia (PWH) and further exploration and subsequent seroprevalence studies are needed to monitor the antibody index. Conclusion: Many factors contribute to the seroprevalence of COVID-19, including demographic profile, occupation, socio-economic status of the country, and personal protective measures taken. Seroprevalence studies are important in making healthcare policies and prioritisation in the early rollout of vaccination for susceptible groups of people and their protection.